Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
Merus B.V.
Merus B.V.
Incyte Corporation
Akeso
DEKA Biosciences
Celldex Therapeutics
Glycotope GmbH
Daiichi Sankyo
Amgen